^
    Back
    Association details:
    Biomarker:EGFR L858R + PIK3CA H1047R + PIK3CA E545K
    Cancer:Lung Adenocarcinoma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Dovepress
    Title:

    Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

    Published date:
    09/09/2021
    Excerpt:
    Herein, we report a case of primary lung adenosquamous carcinoma with concurrent EGFR 21 (L858R) and PIK3CA (H1047R/E545K) mutations…Anlotinib monotherapy was then administered as the third-line treatment, and there was a PR. The patient is currently still receiving treatment and follow-up.
    DOI:
    https://doi.org/10.2147/CMAR.S326094